KRAS and lung carcinoma: Although HOXC10 inhibition showed promising benefits in KRAS-mutant lung cancer bone metastasis in vivo (Fig. 3d, e), we found that the ability of inhibiting bone metastasis by HOXC10 knockdown was significantly diminished 28 days after intracardiac injection (Fig. 3e).